Director at United Therapeutics (UTHR) sells 50 shares under 10b5-1 plan

Rhea-AI Filing Summary

United Therapeutics director Malcolm Jan reported a small planned share sale. On 02/03/2026, he sold 50 shares of United Therapeutics common stock at $474.23 per share in an open-market transaction coded "S." The sale was made under a pre-arranged Rule 10b5-1 trading plan that he entered into on September 11, 2025.

After this transaction, Jan beneficially owned 270 shares of United Therapeutics common stock, held in direct ownership form.

Insider Trade Summary

Net Seller: 50 shares ($23,712)

Net Sell 1 txn

Insider MALCOLM JAN

Role Director

Sold 50 shs ($24K)

Type	Security	Shares	Price	Value
Sale	Common Stock	50	$474.23	$24K

Holdings After Transaction: Common Stock — 270 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MALCOLM JAN

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		S(1)		50	D	$474.23	270	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 11, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did United Therapeutics (UTHR) report for Malcolm Jan?

United Therapeutics director Malcolm Jan reported selling 50 common shares. The sale occurred on 02/03/2026 at a price of $474.23 per share, and was disclosed as an open-market disposition coded "S" in a Form 4 filing.

How many United Therapeutics (UTHR) shares does Malcolm Jan own after this sale?

After the reported sale, Malcolm Jan beneficially owns 270 shares. The Form 4 shows his remaining United Therapeutics common stock holdings as 270 shares, with the ownership form listed as direct, meaning the shares are held in his own name.

Was Malcolm Jan’s United Therapeutics (UTHR) share sale under a Rule 10b5-1 plan?

Yes. The filing states the sale was made under a Rule 10b5-1 plan. A footnote explains that this disposition followed a pre-arranged trading plan entered into by the reporting person on September 11, 2025, providing structured, pre-scheduled sale instructions.

What price did Malcolm Jan receive for his United Therapeutics (UTHR) shares?

The reported sale price was $474.23 per share. According to the Form 4 transaction table, 50 shares of United Therapeutics common stock were sold at a transaction price of $474.23, in a single non-derivative open-market sale coded as an "S" transaction.

What is Malcolm Jan’s role at United Therapeutics (UTHR) in this filing?

Malcolm Jan is identified as a director of United Therapeutics. The relationship section of the Form 4 shows the director box checked, with no officer or 10% owner status indicated, meaning the transaction reflects trading activity by a board member.